文献速递肿瘤 PET/CT骨显像与常规 SPECT

68Ga-FAPI PET/CT 有望检出嫌色细胞肾细胞癌原发及转移灶

68Ga-Fibroblast Activation Protein Inhibitor, a Promising Radiopharmaceutical in PET/CT to Detect the Primary and Metastatic Lesions of Chromophobe Renal Cell Carcinoma.
PubMed 文献 · Clin Nucl Med · 2021-01-01

一例 71 岁男性骨转移患者,18F-FDG PET/CT 未显示可能代表原发肿瘤的异常摄取,随后行 68Ga-成纤维细胞激活蛋白抑制剂 PET/CT,骨转移灶摄取高于 18F-FDG,并发现右肾下极高摄取灶,活检确诊嫌色细胞肾细胞癌。该病例提示 68Ga-FAPI 可能是有前景的放射性药物。

要点

  • 18F-FDG PET/CT 未检出可疑原发肿瘤。
  • 68Ga-FAPI PET/CT 骨转移灶摄取高于 18F-FDG。
  • 68Ga-FAPI PET/CT 发现右肾下极高摄取原发灶。

核心结论

  • 68Ga-成纤维细胞激活蛋白抑制剂可能是诊断肾细胞癌的有前景的放射性药物。

研究设计与样本

  • 本文为单例病例报告,描述一名 71 岁男性骨转移患者的影像检查与病理诊断过程。

主要发现

  • 18F-FDG PET/CT 未观察到可能代表原发肿瘤的异常 18F-FDG 活性。
  • 68Ga-FAPI PET/CT 显示骨转移灶活性高于 18F-FDG。
  • 68Ga-FAPI PET/CT 发现右肾下极另一高摄取灶,可能代表原发肿瘤。
  • 肾活检确诊为嫌色细胞肾细胞癌。

临床怎么用

  • 对于 18F-FDG PET/CT 未显示原发灶的肾细胞癌疑似病例,可考虑行 68Ga-FAPI PET/CT 进一步检测原发肿瘤。

局限性

  • 本文为单例病例报告,结论需更大样本研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

18F-FDG PET/CT was performed to locate the primary lesion in a 71-year-old man with bone metastasis. However, no abnormal 18F-FDG activity likely presenting the primary tumor was observed. 68Ga-fibroblast activation protein inhibitor PET/CT was then performed for further detecting the primary tumor, which showed a higher activity in lesions of bone metastases than 18F-FDG. Additionally, another lesion with intense uptake was observed in the inferior pole of right kidney, likely presenting the primary tumor. A renal biopsy revealed the diagnosis of chromophobe renal cell carcinoma. This case highlighted that 68Ga-fibroblast activation protein inhibitor could be a promising radiopharmaceutical in the diagnosis of renal cell carcinoma.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Pang Y, Wei J, Shang Q, et al. 68Ga-Fibroblast Activation Protein Inhibitor, a Promising Radiopharmaceutical in PET/CT to Detect the Primary and Metastatic Lesions of Chromophobe Renal Cell Carcinoma. Clin Nucl Med. 2021. PMID: 33315682. doi:10.1097/RLU.0000000000003454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。